References
1. Mycotoxins produced by Aspergillus fumigatus species isolated from molded silage: R.J. Cole, et al.; J. Agric. Food Chem. 25: 826 (1977). 2. Novel mammalian cell cycle inhibitors, tryprostatins A, Band other diketopiperazines produced by Aspergillus fumigatus. I. Taxonomy, fermentation, isolation and biological properties: C.B. Cui, et al.; J. Antibiot. 49: 527 (1996). 3. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin: S.K. Rabindran, et al.; Cancer Res. 58: 5850 (1998). 4. Fumitremorgin C reverses multi drug resistance in cells transfected with the breast cancer resistance protein.: S.K. Rabindran, et al.; Cancer Res. 60: 47 (2000). 5. Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation.:Ozvegy, et al.; J. Biol. Chem. 277: 47980 (2002). 6. The role of breast cancer resistance protein in acute lymphoblastic leukemia: S.L. Plasschaert, et al.; Clin. Cancer Res. 9: 5171 (2003). 7. Plasma pharmacokinetics and tissue distribution of the breast cancer resistance protein (BCRP/ABCG2) inhibitor fumitremorgin C in SCID mice bearing T8 tumors: T.S. Garimella, et al.; Cancer Chemother. Phar- macol. 55: 101 (2005). 8. Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes: S. Hauswald, et al.; Clin. Cancer Res. 15: 3705 (2009) 9. Specific inhibitors of the breast cancer resistance protein (BCRP): A. Pick, et al.; ChemMedChem 5: 1498 (2010) 10. Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C: L. Gonzales-Lobato, et al.; Eur. J. Pharmacol. 644: 41 (2010)USBio References
No references available
TDS
NCBI
UniProt
Tech Support
Customer Service
